Details for Patent: 9,101,660

Which drugs does patent 9,101,660 protect, and when does it expire?

Patent 9,101,660 protects ACTOPLUS MET and is included in one NDA.

This patent has thirty-four patent family members in twenty-five countries.

Summary for Patent: 9,101,660

Title:	Solid preparation
Abstract:	The present invention provides a solid preparation containing an insulin sensitizer and an active ingredient (except insulin sensitizers), which is useful as a therapeutic drug for diabetes and the like, and which is superior in preparation characteristics such as content uniformity and dissolution property of the insulin sensitizer and the active ingredient (except insulin sensitizers), preparation hardness and the like.
Inventor(s):	Masahiko Koike, Hiroyoshi Koyama, Naoru Hamaguchi
Assignee:	Takeda Pharmaceutical Co Ltd
Application Number:	US10/530,262
Patent Claim Types: see list of patent claims	Use; Formulation; Compound;

Drugs Protected by US Patent 9,101,660

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Takeda Pharms Usa	ACTOPLUS MET	metformin hydrochloride; pioglitazone hydrochloride	TABLET;ORAL	021842-001	Aug 29, 2005		DISCN	Yes	No			Y
Takeda Pharms Usa	ACTOPLUS MET	metformin hydrochloride; pioglitazone hydrochloride	TABLET;ORAL	021842-002	Aug 29, 2005	AB	RX	Yes	Yes			Y

Foreign Priority and PCT Information for Patent: 9,101,660

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	2002-294045	Oct 7, 2002

PCT Information
PCT Filed	October 06, 2003	PCT Application Number:	PCT/JP03/12781
PCT Publication Date:	April 15, 2004	PCT Publication Number:	WO2004/030700

International Family Members for US Patent 9,101,660

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2003271103
Brazil	0315082
Canada	2501587
China	100427143
China	1717253